Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Arginine and Vasoconstrictor Agents

Research Papers that Mention the Interaction

AIMS It has been suggested that provision of the substrate of nitric oxide (NO) synthesis, L-arginine , might influence the effects of renal vasoconstrictors.
British journal of clinical pharmacology  •  1998  |  View Paper
In addition, there appears to be a relationship between arginine and vasopressor need after bypass surgery.
BMC Cardiovascular Disorders  •  2017  |  View Paper
The authors demonstrate that skin vasoconstriction induced by cigarette smoking in normal volunteers is due to a concomitant enhancement of arginine vasopressin release.
Schweizerische medizinische Wochenschrift  •  1984  |  View Paper
Supplementation of L‐Arg reversed the vasoconstrictor effects of AngII and restored pressure‐dependent diuresis to levels not significantly different from control rats.
Clinical and experimental pharmacology & physiology  •  2014  |  View Paper
L-arginine (L-Arg, 10 &mgr;M) similarly inhibited the vasoconstrictor responses in both strains; however, the inhibitory effect of 100 &mgr;M of L-Arg was greater in MCA from SHR.
Journal of cardiovascular pharmacology  •  2002  |  View Paper
The attenuated vasoconstrictor response to ET-1, but not that to methoxamine, was further attenuated by chronic treatment with L-arginine.
Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi  •  2002  |  View Paper
These findings suggest that the augmented vasoconstriction of the coronary artery induced by ET-1 in hypertensive hearts was due to a reduction in nitric oxide release in coronary vessels and that L-arginine can partially inhibit the vasoconstrictive response of the coronary artery.
American journal of hypertension  •  2000  |  View Paper
9+/-4.8 versus +48.3+/-9.1 mm Hg, P<0.05), and further infusion of the biological ecNOS substrate L-arginine (0.5 g/kg) was ineffective in reversing systemic vasoconstriction (-1% versus 28% vasodilatation, P<0.001).
Circulation  •  1999  |  View Paper
It is concluded that L-arginine-NO pathways act in vivo to oppose peripheral vasoconstrictor influences coupled with central cholinergically mediated activation of the adrenergic system, as produced by physostigmine.
Journal of basic and clinical physiology and pharmacology  •  1994  |  View Paper